Survival and cell cycle kinetics of human prostate cancer cell lines after single- and multifraction exposures to ionizing radiation

International Journal of Radiation Oncology Biology Physics

Volumn 59, Issue 1, 2004, Pages 219-227

  Scott, Susan L ^a   Gumerlock, Paul H ^a   Beckett, Laurel ^a   Li, Yueju ^a   Goldberg, Zelanna ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cell cycle checkpoints; Fractionated radiotherapy; Ionizing radiation; Prostate cancer cells; Radiosensitivity

Indexed keywords

ASSAYS; CELLS; DISEASE CONTROL; IONIZING RADIATION; PATIENT MONITORING; RADIOTHERAPY; TUMORS;

CANCER CELLS; CELL CYCLE; CELL KILLING; FLOW CYTOMETRY;

ONCOLOGY;

ARTICLE; CELL CYCLE; CELL KILLING; CELL KINETICS; CELL SURVIVAL; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IONIZING RADIATION; MALE; MOLECULAR CLONING; PREDICTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR CELL;

CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIATION TOLERANCE;

EID: 16544379887     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.01.027     Document Type: Article

References (39)

1. American Cancer Society. Cancer facts & figures 2002. American Cancer Society; Atlanta, GA; 2002. p. 1-48.
2. NIH. Know your options Understanding treatment choices for prostate cancer. 2002;National Institutes of Health, Bethesda, MD. p. 1-48.
3. Horwitz E.M., Hanlon A.L., Hanks G.E. Update on the treatment of prostate cancer with external beam irradiation. Prostate. 37:1998;195-206.
4. Kirby R. Treatment options for early prostate cancer. Urology. 52:1998;948-962.
5. Coleman N., Stevenson M.A. Biologic basis for radiation oncology. Oncology. 10:1996;399-411.
6. Hall E.J. Radiobiology for the radiologist. 2000;Lippincott Williams & Wilkins, Philadelphia, PA.
7. Dewey W.C., Ling C.C., Meyn R.E. Radiation-induced apoptosis Relevance to radiotherapy. Int J Radiat Oncol Biol Phys. 33:1995;781-796.
8. Bernhard E.J., McKenna W.G., Muschel R.J. Radiosensitivity and the cell cycle. Cancer J. 5:1999;194-204.
9. Schwartz D., Rotter V. p53-dependent cell cycle control Response to genotoxic stress. Sem Cancer Biol. 8:1998;325-336.
10. Bartek J., Lukas J. Mammalian G1- and S-phase checkpoints in response to DNA damage. Curr Opin Cell Biol. 13:2001;738-747.
11. Paulovich A.G., Toczyski D.P., Hartwell L.H. When checkpoints fail. Cell. 88:1997;315-321.
12. Biade S., Stobbe C.C., Chapman J.D. The intrinsic radiosensitivity of some human tumor cells throughout their cell cycles. Radiat Res. 147:1997;416-421.
13. Larner J.M., Lee H., Little R.D., et al. Radiation down-regulates replication origin activity throughout the S phase in mammalian cells. Nucleic Acids Res. 27:1999;803-809.
14. Rezvani M., Ross G., Morris G.M., et al. How valid is the assumption of equal effect per fraction? Radiother Oncol. 53:1999;227-231.
15. Suzuki M., Kase Y., Kanai T., et al. Change in radiosensitivity with fractionated-dose irradiation of carbon-ion beams in five different human cell lines. Int J Radiat Oncol Biol Phys. 48:2000;251-258.
16. Aruga T., Ando K., Iizuka M., et al. Radiosensitivity and cell cycle redistribution of cultured human tumour cells during fractionated daily 2-Gy irradiations. Int J Radiat Oncol Biol Phys. 67:1995;65-70.
17. Sinclair W. Cyclic x-ray responses in mammalian cells in vitro. Radiat Res. 33:1968;620-643.
18. Ponder B.A.J. Cancer genetics. Nature. 411:2001;335-341.
19. Collins K., Jacks T., Pavletich N.P. The cell cycle and cancer. Proc Natl Acad Sci U S A. 94:1997;2776-2778.
20. Molinari M. Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif. 33:2000;261-274.
21. Lara P.N., Kung H.-J., Gumerlock P.H., et al. Molecular biology of prostate carcinogenesis. Crit Rev Oncol Hematol. 32:1999;197-208.
22. Bookstein R., Shew J.-Y., Chen P.-L., et al. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science. 247:1990;712-715.
23. Carroll A.G., Voeller H.J., Sugars L., et al. p53 Oncogene mutations in three human prostate cancer cell lines. Prostate. 23:1993;123-134.
24. INK4A/MITS1) expression in human primary prostate carcinomas. Clin Cancer Res. 3:1997;1889-1897.
25. Rubin S.J., Hallahan D.E., Ashman C.R., et al. Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. J Surg Onc. 46:1991;31-36.
26. Collis S.J., Sangar V.K., Tighe A., et al. Development of a novel rapid assay to assess the fidelity of DNA double-strand-break repair in human tumour cells. Nucleic Acids Res. 30:2002;e1-e6.
27. Zotchev S.B., Protopopova M., Selivanova G. p53 C-terminal interaction with DNA ends and gaps has opposing effect on specific DNA binding by the core. Nucleic Acids Res. 28:2000;4005-4012.
28. Yamane A., Katayama E., Tsuruo T. p53 contains a DNA break-binding motif similar to the functional part of BRCT-related region of Rb. Oncogene. 20:2001;2859-2867.
29. Sramkoski R.M., Pretlow I., Thomas G., et al. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim. 35:1999;403-409.
30. Gadbois D., Bradbury E., Lehnert B. Control of radiation-induced G1 arrest by cell-substratum interactions. Cancer Res. 57:1997;1151-1156.
31. Scott S.L., Higdon R., Beckett L., et al. BCL2 antisense reduces prostate cancer cell survival following irradiation. Cancer Biother Radiopharm. 17:2002;647-656.
32. Deweese T.L., Shipman J.M., Dillehay L.E., et al. Sensitivity of human prostate carcinoma cell lines to low dose rate radiation exposure. J Urol. 159:1998;591-598.
33. Powell S.N., DeFrank J., Connell P., et al. Differential sensitivity of p53(-) and p53 (+) cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res. 55:1995;1643-1648.
34. Russell K.J., Wiens L.W., Demers G.W., et al. Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells. Cancer Res. 55:1995;1639-1642.
35. MathSoft I. S-Plus. 6.0 ed. Seattle, WA: MathSoft, Inc.; 2000.
36. SAS Institute I. SAS. 8 ed. Cary, NC: SAS Institute, Inc.; 1999.
37. Alpen E.L. Radiation biophysics. 1998;Academic Press, San Diego, CA.
38. Mitchell C.R., Folkard M., Joiner M.C. Effects of exposure to low-dose-rate Co-60 gamma rays on human tumor cells in vitro. Radiat Res. 158:2002;311-318.
39. Latz D., Fleckenstein K., Eble M., et al. Radiosensitizing potential of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) within the cell cycle in vitro. Int J Radiat Oncol Biol Phys. 41:1998;875-882.